Study of Tamibarotene in Patients With ADPKD
Clinical trial of tamibarotene in patients with Autosomal Dominant Polycystic Kidney Disease
- EligibilityCriteria: Inclusion Criteria:  Patients diagnosed as ADPKD by modified Pei-Ravine eGFR(CKD-EPI) is equal to or greater than 60 mL/min/1.73m^2 Patients who are judged to be hard to treat with tolvaptan or who do not wish to be treated with tolvaptan, at the time of obtaining consent Patients with systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg. For patients receiving angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists, the dose must be constant for at least 6 weeks before obtaining informed consent  Exclusion Criteria:  Women who are pregnant or may be pregnant Nursing mother  Females with childbearing potential or male subjects with a fertile partner who is unable to use contraception for the following periods:  Female: From informed consent to 2 years after the last administration of the study drug Male: From informed consent to 6 months after the last administration of the study drug Patients within 12 weeks from the last dose of a drug that affects renal cysts, such as tolvaptan, to the first dose of the study drug Patients with complications of intracranial aneurysm, malignant tumor, uncontrolled diabetes, osteoporosis, uncontrolled dyslipidemia, or abnormal liver function - HealthyVolunteers: No - Gender: All - MinimumAge: 26 Years - MaximumAge: 55 Years - StdAgeList: Adult